|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARMC5 |
Gene summary for ARMC5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARMC5 | Gene ID | 79798 |
| Gene name | armadillo repeat containing 5 | |
| Gene Alias | AIMAH2 | |
| Cytomap | 16p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0001701 | UniProtAcc | Q96C12 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79798 | ARMC5 | LZE24T | Human | Esophagus | ESCC | 4.54e-10 | 2.33e-01 | 0.0596 |
| 79798 | ARMC5 | P1T-E | Human | Esophagus | ESCC | 6.52e-03 | 2.20e-01 | 0.0875 |
| 79798 | ARMC5 | P2T-E | Human | Esophagus | ESCC | 1.15e-29 | 5.08e-01 | 0.1177 |
| 79798 | ARMC5 | P4T-E | Human | Esophagus | ESCC | 1.92e-05 | 1.10e-01 | 0.1323 |
| 79798 | ARMC5 | P8T-E | Human | Esophagus | ESCC | 1.75e-08 | 1.50e-01 | 0.0889 |
| 79798 | ARMC5 | P10T-E | Human | Esophagus | ESCC | 5.51e-16 | 1.98e-01 | 0.116 |
| 79798 | ARMC5 | P11T-E | Human | Esophagus | ESCC | 1.35e-07 | 2.69e-01 | 0.1426 |
| 79798 | ARMC5 | P12T-E | Human | Esophagus | ESCC | 8.18e-12 | 2.57e-01 | 0.1122 |
| 79798 | ARMC5 | P15T-E | Human | Esophagus | ESCC | 2.64e-03 | 8.91e-02 | 0.1149 |
| 79798 | ARMC5 | P16T-E | Human | Esophagus | ESCC | 4.10e-05 | 1.29e-01 | 0.1153 |
| 79798 | ARMC5 | P17T-E | Human | Esophagus | ESCC | 8.51e-03 | 1.67e-01 | 0.1278 |
| 79798 | ARMC5 | P20T-E | Human | Esophagus | ESCC | 3.49e-07 | 2.57e-01 | 0.1124 |
| 79798 | ARMC5 | P22T-E | Human | Esophagus | ESCC | 1.11e-05 | 7.98e-02 | 0.1236 |
| 79798 | ARMC5 | P23T-E | Human | Esophagus | ESCC | 6.24e-08 | 1.67e-01 | 0.108 |
| 79798 | ARMC5 | P24T-E | Human | Esophagus | ESCC | 2.65e-05 | 9.66e-02 | 0.1287 |
| 79798 | ARMC5 | P26T-E | Human | Esophagus | ESCC | 1.91e-16 | 3.11e-01 | 0.1276 |
| 79798 | ARMC5 | P27T-E | Human | Esophagus | ESCC | 6.05e-08 | 1.42e-01 | 0.1055 |
| 79798 | ARMC5 | P28T-E | Human | Esophagus | ESCC | 1.53e-10 | 1.95e-01 | 0.1149 |
| 79798 | ARMC5 | P30T-E | Human | Esophagus | ESCC | 4.03e-08 | 2.92e-01 | 0.137 |
| 79798 | ARMC5 | P31T-E | Human | Esophagus | ESCC | 2.26e-08 | 8.92e-02 | 0.1251 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
| GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:00073698 | Esophagus | ESCC | gastrulation | 115/8552 | 185/18723 | 4.35e-06 | 4.64e-05 | 115 |
| GO:00017044 | Esophagus | ESCC | formation of primary germ layer | 75/8552 | 121/18723 | 2.17e-04 | 1.36e-03 | 75 |
| GO:004211018 | Esophagus | ESCC | T cell activation | 256/8552 | 487/18723 | 1.18e-03 | 5.87e-03 | 256 |
| GO:19031317 | Esophagus | ESCC | mononuclear cell differentiation | 226/8552 | 426/18723 | 1.20e-03 | 5.88e-03 | 226 |
| GO:00066946 | Esophagus | ESCC | steroid biosynthetic process | 98/8552 | 173/18723 | 2.34e-03 | 1.03e-02 | 98 |
| GO:00302176 | Esophagus | ESCC | T cell differentiation | 137/8552 | 257/18723 | 8.09e-03 | 2.87e-02 | 137 |
| GO:00192168 | Esophagus | ESCC | regulation of lipid metabolic process | 172/8552 | 331/18723 | 1.20e-02 | 4.02e-02 | 172 |
| GO:00300984 | Esophagus | ESCC | lymphocyte differentiation | 192/8552 | 374/18723 | 1.52e-02 | 4.93e-02 | 192 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARMC5 | SNV | Missense_Mutation | c.1510G>T | p.Ala504Ser | p.A504S | protein_coding | tolerated(0.31) | possibly_damaging(0.709) | TCGA-A2-A1G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | ||
| ARMC5 | SNV | Missense_Mutation | c.1330N>A | p.Val444Met | p.V444M | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ARMC5 | SNV | Missense_Mutation | c.1365N>G | p.Ile455Met | p.I455M | protein_coding | deleterious(0.05) | probably_damaging(0.976) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| ARMC5 | SNV | Missense_Mutation | rs564560701 | c.3056T>G | p.Val1019Gly | p.V1019G | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.791) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| ARMC5 | SNV | Missense_Mutation | novel | c.1162C>G | p.Pro388Ala | p.P388A | protein_coding | tolerated(0.51) | benign(0.122) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| ARMC5 | SNV | Missense_Mutation | c.2811N>A | p.Phe937Leu | p.F937L | protein_coding | deleterious(0) | possibly_damaging(0.718) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | ||
| ARMC5 | SNV | Missense_Mutation | rs771976948 | c.1007N>T | p.Pro336Leu | p.P336L | protein_coding | deleterious(0.02) | probably_damaging(0.992) | TCGA-D8-A1Y3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| ARMC5 | SNV | Missense_Mutation | rs372473237 | c.1645N>T | p.Arg549Trp | p.R549W | protein_coding | deleterious(0.02) | possibly_damaging(0.886) | TCGA-E2-A14O-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD | |
| ARMC5 | deletion | Frame_Shift_Del | novel | c.3044delT | p.Leu1015CysfsTer5 | p.L1015Cfs*5 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
| ARMC5 | SNV | Missense_Mutation | rs539440145 | c.1285C>T | p.Arg429Cys | p.R429C | protein_coding | deleterious(0.01) | possibly_damaging(0.899) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |